CAS No.: 1013915-71-3
(R)-5-((3-((6,8-Dibromochroman-4-yl)amino)propyl)amino)thieno[3,2-b]pyridin-7(4H)-one Catalog No. CSN20260
Synonyms: REP-3123
CRS-3123 is a methionyl-tRNA synthetase inhibitor potentially for the treatment of enteric infections.
| 规格 | 价格 | 促销价格 | 库存 | 数量 |
|---|
400-920-2911
sales@csnpharm.cn
tech@csnpharm.cn
纯度 & 质量文件
批次:
靶点选择性
生物活性
- 描述
- 临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点 NCT01551004 Clostridium Difficile Colitis Phase 1 Completed - United States, Maryland ... more >> Johns Hopkins Bayview Medical Center - Infectious Diseases Baltimore, Maryland, United States, 21224-2735 Collapse << NCT02106338 Clostridium Difficile Infectio... more >>n Collapse << Phase 1 Completed - United States, Kansas ... more >> Quintiles Phase I Services - Overland Park Overland Park, Kansas, United States, 66211-1553 Collapse << - 参考文献
- [1] Basseres E, Endres BT, et al. Novel antibiotics in development to treat Clostridium difficile infection. Curr Opin Gastroenterol. 2017 Jan;33(1):1-7.
- [2] Nayak SU, Griffiss JM, et al. Safety, tolerability, systemic exposure and metabolism of CRS3123, a methionyl-tRNA synthetase inhibitor developed for treatment of Clostridium difficile infections, in a Phase I study. Antimicrob Agents Chemother. 2017 Jun 5. pii: AAC.02760-16.
实验方案
- 计算器
- 储存液制备
技术信息
| CAS号 | 1013915-71-3 | 储存条件 |
|
|
| 分子式 | C19H19Br2N3O2S | 运输 | 蓝冰 | |
| 分子量 | 513.25 | 别名 | REP-3123 |
